These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

527 related items for PubMed ID: 9079232

  • 1. Pharmacological and toxicological studies of the new angiotensin converting enzyme inhibitor moexipril hydrochloride.
    Friehe H, Ney P.
    Arzneimittelforschung; 1997 Feb; 47(2):132-44. PubMed ID: 9079232
    [Abstract] [Full Text] [Related]

  • 2. Moexipril, a new angiotensin-converting enzyme (ACE) inhibitor: pharmacological characterization and comparison with enalapril.
    Edling O, Bao G, Feelisch M, Unger T, Gohlke P.
    J Pharmacol Exp Ther; 1995 Nov; 275(2):854-63. PubMed ID: 7473177
    [Abstract] [Full Text] [Related]

  • 3. Preclinical safety studies of the combination moexipril hydrochloride/hydrochlorothiazide.
    Gietl R, Friehe H, Ney P.
    Arzneimittelforschung; 1998 Apr; 48(4):365-70. PubMed ID: 9608878
    [Abstract] [Full Text] [Related]

  • 4. CI-906 and CI-907: new orally active nonsulfhydryl angiotensin-converting enzyme inhibitors.
    Kaplan HR, Cohen DM, Essenburg AD, Major TC, Mertz TE, Ryan MJ.
    Fed Proc; 1984 Apr; 43(5):1326-9. PubMed ID: 6323223
    [Abstract] [Full Text] [Related]

  • 5. Pharmacological and clinical profile of moexipril: a concise review.
    Chrysant SG, Chrysant GS.
    J Clin Pharmacol; 2004 Aug; 44(8):827-36. PubMed ID: 15286086
    [Abstract] [Full Text] [Related]

  • 6. Moexipril shows a long duration of action related to an extended pharmacokinetic half-life and prolonged ACE inhibition.
    Cawello W, Boekens H, Waitzinger J, Miller U.
    Int J Clin Pharmacol Ther; 2002 Jan; 40(1):9-17. PubMed ID: 11837383
    [Abstract] [Full Text] [Related]

  • 7. Pharmacological profile and clinical use of moexipril.
    Chrysant SG, Chrysant GS.
    Expert Rev Cardiovasc Ther; 2003 Sep; 1(3):345-52. PubMed ID: 15030263
    [Abstract] [Full Text] [Related]

  • 8. Inhibition of angiotensin I-converting enzyme with S 9490: biochemical effects, interspecies differences, and role of sodium diet in hemodynamic effects.
    Laubie M, Schiavi P, Vincent M, Schmitt H.
    J Cardiovasc Pharmacol; 1984 Sep; 6(6):1076-82. PubMed ID: 6084763
    [Abstract] [Full Text] [Related]

  • 9. Antihypertensive effects of CI-907 (indolapril): a novel nonsulfhydryl angiotensin converting enzyme inhibitor.
    Ryan MJ, Boucher DM, Cohen DM, Essenburg AD, Major TC, Mertz TE, Olszewski BJ, Randolph AE, Singer RM, Kaplan HR.
    J Pharmacol Exp Ther; 1984 Feb; 228(2):312-8. PubMed ID: 6319675
    [Abstract] [Full Text] [Related]

  • 10. Moexipril. A review of its use in the management of essential hypertension.
    Brogden RN, Wiseman LR.
    Drugs; 1998 Jun; 55(6):845-60. PubMed ID: 9617599
    [Abstract] [Full Text] [Related]

  • 11. Antihypertensive action of a novel orally active angiotensin converting enzyme inhibitor altiopril calcium (MC-838) in several hypertensive models of rats: comparison with captopril.
    Aono J, Koga T, Yamazaki T, Shiraki Y, Sakai K.
    Arch Int Pharmacodyn Ther; 1988 Jun; 292():203-22. PubMed ID: 3293542
    [Abstract] [Full Text] [Related]

  • 12. Antihypertensive activity of alacepril, an orally active angiotensin converting enzyme inhibitor, in renal hypertensive rats and dogs.
    Takeyama K, Minato H, Fukuya F, Kawahara S, Hosoki K, Kadokawa T.
    Arzneimittelforschung; 1985 Jun; 35(10):1502-7. PubMed ID: 3000389
    [Abstract] [Full Text] [Related]

  • 13. Impact of antihypertensive therapy on postmenopausal osteoporosis: effects of the angiotensin converting enzyme inhibitor moexipril, 17beta-estradiol and their combination on the ovariectomy-induced cancellous bone loss in young rats.
    Stimpel M, Jee WS, Ma Y, Yamamoto N, Chen Y.
    J Hypertens; 1995 Dec; 13(12 Pt 2):1852-6. PubMed ID: 8903666
    [Abstract] [Full Text] [Related]

  • 14. Antihypertensive properties of a new long-acting angiotensin converting enzyme inhibitor in renin-dependent and independent hypertensive models.
    Nagata S, Takeyama K, Fukuya F, Nagai R, Hosoki K, Nishimura K, Deguchi T, Karasawa T.
    Arzneimittelforschung; 1995 Aug; 45(8):853-8. PubMed ID: 7575746
    [Abstract] [Full Text] [Related]

  • 15. Possible involvement of ATP-dependent K-channel related mechanisms in the antihypertensive and cough suppressant effects of the novel ACE inhibitor (2S, 3aS, 7aS)-1-(N2-nicotinoyl-L-lysyl-gamma-D-glutamyl)octahydro-1H- indole-2-carboxylic acid.
    Nagata S, Takeyama K, Hosoki K, Karasawa T.
    Arzneimittelforschung; 1997 Jun; 47(6):726-30. PubMed ID: 9239450
    [Abstract] [Full Text] [Related]

  • 16. General pharmacology of the new antimuscarinic compound vamicamide.
    Yamamoto T, Honbo T, Tokoro K, Kojimoto Y, Kodama R, Ohtsuka M, Shimomura K.
    Arzneimittelforschung; 1995 Dec; 45(12):1274-84. PubMed ID: 8595084
    [Abstract] [Full Text] [Related]

  • 17. Moexipril and quinapril inhibition of tissue angiotensin-converting enzyme activity in the rat: evidence for direct effects in heart, lung and kidney and stimulation of prostacyclin generation.
    Torsello A, Locatelli V, Cella SG, Sanguini AM, Berti F.
    J Endocrinol Invest; 2003 Jan; 26(1):79-83. PubMed ID: 12602539
    [Abstract] [Full Text] [Related]

  • 18. Tricenter assessment of the efficacy of the ACE inhibitor, moexipril, by ambulatory blood pressure monitoring.
    White WB, Whelton A, Fox AA, Stimpel M, Kaihlanen PM.
    J Clin Pharmacol; 1995 Mar; 35(3):233-8. PubMed ID: 7608310
    [Abstract] [Full Text] [Related]

  • 19. General pharmacology of the non-sulfhydryl angiotensin converting enzyme inhibitor N-[8-amino-1(S)-carboxyoctyl]-L-alanyl-L-proline.
    Shirota M, Hayashi M, Kajiwara Y, Kitabatake K, Uruno T, Kubota K.
    Arzneimittelforschung; 1993 Nov; 43(11):1169-74. PubMed ID: 8292059
    [Abstract] [Full Text] [Related]

  • 20. Do the cardiovascular effects of angiotensin-converting enzyme (ACE) I involve ACE-independent mechanisms? new insights from proline-rich peptides of Bothrops jararaca.
    Ianzer D, Santos RA, Etelvino GM, Xavier CH, de Almeida Santos J, Mendes EP, Machado LT, Prezoto BC, Dive V, de Camargo AC.
    J Pharmacol Exp Ther; 2007 Aug; 322(2):795-805. PubMed ID: 17475904
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.